Breast-specific gamma imaging (BSGI) developer Dilon Diagnostics is touting the results of a study that found that the company's molecular breast imaging technology is accurate in establishing tumor size within 5 mm after neoadjuvant chemotherapy.
The study, led by Christine Teal, MD, chief of breast surgery at George Washington University Medical Center in Washington, DC, included 15 consecutive patients who had BSGI before and after neoadjuvant chemotherapy.
BSGI was determined to accurately reflect pathologic tumor size within 5 mm after neoadjuvant chemotherapy in patients with breast cancer. Teal and colleagues noted that BSGI was less reliable in detecting residual microscopic disease in these patients, but that BSGI proved to be a valuable tool for determining patient response to neoadjuvant chemotherapy.
Results were presented recently at the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium in Washington, DC, according to the Newport News, VA-based company.
Related Reading
Dilon reports positive BSGI study, October 7, 2010
Dilon touts low radiation in BSGI study, October 5, 2010
Dilon reports positive BSGI research, June 30, 2010
Dilon touts BSGI measurement study, May 3, 2010
BSGI proves best at detecting invasive lobular cancer, February 11, 2009
Copyright © 2010 AuntMinnie.com
